The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / New Paradigm Investing


Subject:  Re: PDLI - Tinker and All Date:  6/13/2006  6:32 PM
Author:  TMoney2 Number:  27146 of 116518

6/12/2006- 2:36:59 PM S&P DOWNGRADES SHARES OF PROTEIN DESIGN LABS TO BUY FROM STRONG BUY (PDLI 18.13 ): We still think the company's royalty stream is worth more than the current market cap, but we are less positive on the pipeline and see a more cautious FDA adding risk. We believe royalty growth should stay strong, largely due to sales gains for several Genentech (DNA 79.7*****) drugs. In the pipeline, we are still positive on daclizumab and ularitide, but are now neutral on volociximab. Based on NPV analysis, we are lowering our 12-month target price to $30 from $35 on lower value for the pipeline and currently approved products. /F.DiLorenzo-CFA

Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us